Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants
Bifidobacterium- und Lactobacillus-Probiotika und Darmdysbiose bei Frühgeborenen
JAMA Pediatrics · 01.10.2024 · 178 (10) · 985
DOI: 10.1001/jamapediatrics.2024.2626 ↗Auf einen Blick
Multistrain-Probiotika senkten bei Frühgeborenen die MDRO+-Kolonisation an Tag 30 nicht. Die Mikrobiota verschob sich jedoch in Richtung Eubiose.
Fragestellung
Wirken Bifidobacterium- und Lactobacillus-Probiotika bei Frühgeborenen gegen MDRO+-Kolonisation und beeinflussen sie die frühe Mikrobiomentwicklung?
Methode
Multizentrische, doppelblinde, placebokontrollierte, gruppensequenzielle Phase-3-RCT in 18 deutschen Neonatalstationen; 28 Tage Probiotika ab den ersten 72 Lebensstunden.
Ergebnisse
643 randomisierte Frühgeborene; 618 mit Follow-up an Tag 30. MDRO+-Kolonisation: 37,4 % vs. 37,5 %; adjustiertes RR 0,99 (95 %-KI 0,54–1,81; P=.97). Eubiose-Scores höher unter Probiotika.
Einschränkungen
Die Rekrutierung wurde nach Interimsanalyse gestoppt.
Schlussfolgerung der Autor:innen
Multistrain-Probiotika reduzierten die MDRO+-Kolonisation an Tag 30 nicht, modulierten das Mikrobiom aber in Richtung Eubiose.
Kernaussagen
- MDRO+-Kolonisation an Tag 30 unverändert: 37,4 % vs. 37,5 %
- Eubiose-Scores unter Probiotika höher als unter Placebo
- Sicherheitsendpunkte ähnlich in beiden Gruppen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Pediatrics, erschienen am 01.10.2024. Verfasst von Thea Van Rossum und 44 weiteren Autor:innen. Beteiligte Einrichtung: European Molecular Biology Laboratory, Heidelberg, Germany. Hauptthemen laut MEDLINE: Probiotics, Infant, Premature, Dysbiosis, Gastrointestinal Microbiome. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Neonatologie
Abstract (Originalsprache)
Importance The effects of probiotic interventions on colonization with resistant bacteria and early microbiome development in preterm infants remain to be clarified.
Objective
To examine the efficacy of Bifidobacterium longum subsp infantis , Bifidobacterium animalis subsp lactis (BB-12), and Lactobacillus acidophilus (La-5) probiotics to prevent colonization with multidrug-resistant organisms or highly epidemic bacteria (MDRO+) and to shape the microbiome of preterm infants toward the eubiotic state of healthy full-term infants. Design, Setting, and Participants The multicenter, double-blinded, placebo-controlled, group sequential, phase 3 Priming Immunity at the Beginning of Life (PRIMAL) randomized clinical trial, conducted from April 2018 to June 2020, included infants with gestational age of 28 to 32 weeks at 18 German neonatal units. Data analyses were conducted from March 2020 to August 2023.
Intervention
A total of 28 days of multistrain probiotics diluted in human milk/formula starting within the first 72 hours of life. Main Outcomes and Measures Colonization with MDRO+ at day 30 of life (primary end point), late-onset sepsis and severe gastrointestinal complication (safety end points), and gut dysbiosis, ie, deviations from the microbiome of healthy, term infants (eubiosis score) based on 16-subunit ribosomal RNA and metagenomic sequencing.
Results
Among the 643 infants randomized until the stop of recruitment based on interim results, 618 (median [IQR] gestational age, 31.0 [29.7-32.1] weeks; 333 male [53.9%]; mean [SD] birth weight, 1502 [369] g) had follow-up at day 30. The interim analysis with all available data from 219 infants revealed MDRO+ colonization in 43 of 115 infants (37.4%) in the probiotics group and in 39 of 104 infants (37.5%) in the control group (adjusted risk ratio, 0.99; 95% CI, 0.54-1.81; P = .97). Safety outcomes were similar in both groups, ie, late-onset sepsis (probiotics group: 8 of 316 infants [2.5%]; control group: 12 of 322 infants [3.7%]) and severe gastrointestinal complications (probiotics group: 6 of 316 infants [1.9%]; control group: 7 of 322 infants [2.2%]). The probiotics group had higher eubiosis scores than the control group at the genus level (254 vs 258 infants; median scores, 0.47 vs 0.41; odds ratio [OR], 1.07; 95% CI, 1.02-1.13) and species level (96 vs 83 infants; median scores, 0.87 vs 0.59; OR, 1.28; 95% CI, 1.19-1.38). Environmental uptake of the B infantis probiotic strain in the control group was common (41 of 84 [49%]), which was highly variable across sites and particularly occurred in infants with a sibling who was treated with probiotics. Conclusions and Relevance Multistrain probiotics did not reduce the incidence of MDRO+ colonization at day 30 of life in preterm infants but modulated their microbiome toward eubiosis. Trial Registration German Clinical Trials Register: DRKS00013197
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- European Molecular Biology Laboratory, Heidelberg, Germany.
- Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
- Department of Pediatrics, University Hospital Mainz, Mainz, Germany.
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.
- Department of Pediatrics, University Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany.
Zitieren
APA
Van Rossum, T., Haiß, A., Knoll, R. L., Marißen, J., Podlesny, D., Pagel, J., Bleskina, M., Vens, M., Fortmann, I., Siller, B., Ricklefs, I., Klopp, J., Hilbert, K., Meyer, C., Thielemann, R., Goedicke-Fritz, S., Kuntz, M., Wieg, C., Teig, N., …, & Härtel, C. (2024). Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants. JAMA Pediatrics, 178(10), 985. https://doi.org/10.1001/jamapediatrics.2024.2626
Vancouver
Van Rossum T, Haiß A, Knoll RL, Marißen J, Podlesny D, Pagel J, et al. Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants. JAMA Pediatrics. 2024;178(10):985. doi:10.1001/jamapediatrics.2024.2626
BibTeX
@article{VanRossum2024,
author = {Van Rossum, Thea and Haiß, Annette and Knoll, Rebecca L and Marißen, Janina and Podlesny, Daniel and Pagel, Julia and Bleskina, Marina and Vens, Maren and Fortmann, Ingmar and Siller, Bastian and Ricklefs, Isabell and Klopp, Jonas and Hilbert, Katja and Meyer, Claudius and Thielemann, Roman and Goedicke-Fritz, Sybelle and Kuntz, Martin and Wieg, Christian and Teig, Norbert and Körner, Thorsten and Kribs, Angela and Hudalla, Hannes and Knuf, Markus and Stein, Anja and Gille, Christian and Bagci, Soyhan and Dohle, Frank and Proquitté, Hans and Olbertz, Dirk M and Schmidt, Esther and Koch, Lutz and Pirr, Sabine and Rupp, Jan and Spiegler, Juliane and Kopp, Matthias V and Göpel, Wolfgang and Herting, Egbert and Forslund, Sofia K and Viemann, Dorothee and Zemlin, Michael and Bork, Peer and Gehring, Stephan and König, Inke R and Henneke, Philipp and Härtel, Christoph},
title = {Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants},
journal = {JAMA Pediatrics},
year = {2024},
volume = {178},
number = {10},
pages = {985},
doi = {10.1001/jamapediatrics.2024.2626}
}
EUVIMED